Amgen AMGN Aranesp — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amgen's aranesp — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amgen's aranesp — total revenues?
- Amgen (AMGN) reported aranesp — total revenues of $311M in Q1 2026.
- How has Amgen's aranesp — total revenues changed year-over-year?
- Amgen's aranesp — total revenues decreased by 8.5% year-over-year, from $340M to $311M.
- What is the long-term trend for Amgen's aranesp — total revenues?
- Over 4 years (2021 to 2025), Amgen's aranesp — total revenues has grown at a -1.6% compound annual growth rate (CAGR), from $1.48B to $1.39B.
- What does aranesp — total revenues mean?
- This metric represents the total gross sales generated from the Aranesp product line, a therapeutic agent used to treat anemia associated with chronic kidney disease and chemotherapy. It reflects the market demand, pricing power, and competitive positioning of this specific biologic asset within the company's broader portfolio. Monitoring this revenue stream helps assess the lifecycle stage of the product as it faces potential biosimilar competition and shifts in clinical treatment standards.